<DOC>
	<DOCNO>NCT00396604</DOCNO>
	<brief_summary>The study design obtain safety efficacy data three dose level indacaterol deliver via SDDPI patient COPD . All patient receive 1 day treatment follow : indacaterol 150 µg , once- indacaterol 300 µg , indacaterol 600 µg , placebo , formoterol . Each treatment day follow washout-period 1 week .</brief_summary>
	<brief_title>Indacaterol Delivered Via Single Dose Dry Powder Inhaler ( SDDPI ) Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<criteria>Male female age 4075 year COPD symptom cough , sputum production , shortness breath . Smoking history least 10 pack year FEV1 less 65 % predict normal value least 0.75 L Prebronchodilator FEV1/FVC le 70 % A history asthma COPD diagnosis age 40 Hospitalization COPD exacerbation within previous 6 week Respiratory tract infection within 6 week Use longterm oxygen therapy Diabetes type I uncontrolled diabetes type II Clinically relevant laboratory abnormality clinically significant condition Corrected QT interval ( QTc ) 430 m male 450 m female , history QTc prolongation . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>indacaterol</keyword>
	<keyword>long act beta agonist</keyword>
</DOC>